About the Company
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AERI News
Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of ...
Chairs from Aerie Pharmaceuticals & Santen Inc Invitation to join Ophthalmic Drugs
SAE Media Group reports: Mitchell de Long, Vice President, Chemistry from Aerie Pharmaceuticals and Naj Sharif, Vice President, Ophthalmology Innovation Center from Santen Inc USA cordially invite ...
Daniel Janney's Net Worth
Inc., AERIE PHARMACEUTICALS INC, VIVEVE MEDICAL, INC., and ELLIE MAE INC. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second ...
Aerie Promo Codes • July 2024
Receive your 10% coupon by joining Aerie's mailing list right away. When you join Real Rewards, you can save more money. Win-win situation: your friends enjoy an extra 20% off and you get 25% off ...
Beyond Air Inc (XAIR)
Shares of Recro Pharma, Inc. (NASDAQ:REPH) plunged 34% on Mar 25, following a complete response letter (“CRL”) to the new drug application (“NDA”) seeking... Aerie Pharmaceuticals ...
CME Overview
This continuing medical education activity is provided by OSN New York 2020 is supported, in part, by independent medical education grants from Aerie Pharmaceuticals, Inc.; Alcon Vision ...
Arrowhead Pharmaceuticals: Driving To Commercialization
Arrowhead Pharmaceuticals has a promising pipeline of drug candidates based on RNAi methodology. Read why investors may want ...
Elite Pharmaceuticals, Inc. (ELTP)
Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - July 1, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a ...
Deerfield Mgmt III, L.P.'s Net Worth
Who is Deerfield Mgmt III, L.P.? Deerfield Mgmt III, L.P. has an estimated net worth of $156 Million. This is based on reported shares across multiple companies, which include Fractyl Health, Inc ...
PMVP PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product ...
Madrigal Pharmaceuticals, Inc. (MDGL)
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday ...
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...